ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antibody-radionuclide Conjugates Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-14P16309
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Antibody radionuclide Conjugates Market Research Report 2023
BUY CHAPTERS

Global Antibody-radionuclide Conjugates Market Research Report 2025

Code: QYRE-Auto-14P16309
Report
May 2025
Pages:93
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals

Antibody-radionuclide Conjugates Market Size

The global market for Antibody-radionuclide Conjugates was valued at US$ 1975 million in the year 2024 and is projected to reach a revised size of US$ 5993 million by 2031, growing at a CAGR of 17.4% during the forecast period.

Antibody-radionuclide Conjugates Market

Antibody-radionuclide Conjugates Market

Antibody-radionuclide Conjugates is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The Antibody-radionuclide Conjugates Market is driven by the increasing interest in targeted cancer therapy and the potential of combining monoclonal antibodies with radioactive isotopes to deliver precise treatment. Antibody-radionuclide conjugates offer a highly focused approach to treating cancer by delivering radiation directly to tumor cells, minimizing damage to healthy tissue. As the understanding of cancer biology and immunotherapy advances, and personalized treatment options gain prominence, the demand for these conjugates continues to grow. Innovations in conjugation techniques, radiolabeling methods, and the expansion of the oncology pipeline further contribute to market expansion. However, a significant challenge for this market is the need to address complex drug development processes, optimize safety and efficacy, and navigate regulatory standards while ensuring affordability and accessibility for patients. Overcoming production challenges, minimizing off-target effects, and managing development costs are ongoing hurdles. Additionally, the market faces competition from other cancer therapies and the need for continuous research and development to enhance the efficiency and precision of antibody-radionuclide conjugates. Striking a balance between providing safe, effective, and accessible targeted cancer treatments while addressing scientific and regulatory challenges is essential for the continued growth of the Antibody-radionuclide Conjugates Market.
This report aims to provide a comprehensive presentation of the global market for Antibody-radionuclide Conjugates, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-radionuclide Conjugates.
The Antibody-radionuclide Conjugates market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody-radionuclide Conjugates market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody-radionuclide Conjugates companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Antibody-radionuclide Conjugates Market Report

Report Metric Details
Report Name Antibody-radionuclide Conjugates Market
Accounted market size in year US$ 1975 million
Forecasted market size in 2031 US$ 5993 million
CAGR 17.4%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, Nordic Nanovector, Philogen, RadioMedix, Telix Pharmaceuticals, Orano Med, Actinium Pharmaceuticals, Y-mAbs Therapeutics, Fusion Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Antibody-radionuclide Conjugates company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Antibody-radionuclide Conjugates Market growing?

Ans: The Antibody-radionuclide Conjugates Market witnessing a CAGR of 17.4% during the forecast period 2025-2031.

What is the Antibody-radionuclide Conjugates Market size in 2031?

Ans: The Antibody-radionuclide Conjugates Market size in 2031 will be US$ 5993 million.

Who are the main players in the Antibody-radionuclide Conjugates Market report?

Ans: The main players in the Antibody-radionuclide Conjugates Market are Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, Nordic Nanovector, Philogen, RadioMedix, Telix Pharmaceuticals, Orano Med, Actinium Pharmaceuticals, Y-mAbs Therapeutics, Fusion Pharmaceuticals

What are the Application segmentation covered in the Antibody-radionuclide Conjugates Market report?

Ans: The Applications covered in the Antibody-radionuclide Conjugates Market report are Solid Tumor, Non Hodgkin Lymphoma

What are the Type segmentation covered in the Antibody-radionuclide Conjugates Market report?

Ans: The Types covered in the Antibody-radionuclide Conjugates Market report are Beta-emitting, Targeted Alpha Therapy

Recommended Reports

Radiopharmaceutical Therapy

Antibody Drug Conjugates

Radiation Therapy Devices

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody-radionuclide Conjugates Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Beta-emitting
1.2.3 Targeted Alpha Therapy
1.3 Market by Application
1.3.1 Global Antibody-radionuclide Conjugates Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Solid Tumor
1.3.3 Non Hodgkin Lymphoma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody-radionuclide Conjugates Market Perspective (2020-2031)
2.2 Global Antibody-radionuclide Conjugates Growth Trends by Region
2.2.1 Global Antibody-radionuclide Conjugates Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antibody-radionuclide Conjugates Historic Market Size by Region (2020-2025)
2.2.3 Antibody-radionuclide Conjugates Forecasted Market Size by Region (2026-2031)
2.3 Antibody-radionuclide Conjugates Market Dynamics
2.3.1 Antibody-radionuclide Conjugates Industry Trends
2.3.2 Antibody-radionuclide Conjugates Market Drivers
2.3.3 Antibody-radionuclide Conjugates Market Challenges
2.3.4 Antibody-radionuclide Conjugates Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody-radionuclide Conjugates Players by Revenue
3.1.1 Global Top Antibody-radionuclide Conjugates Players by Revenue (2020-2025)
3.1.2 Global Antibody-radionuclide Conjugates Revenue Market Share by Players (2020-2025)
3.2 Global Antibody-radionuclide Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibody-radionuclide Conjugates Revenue
3.4 Global Antibody-radionuclide Conjugates Market Concentration Ratio
3.4.1 Global Antibody-radionuclide Conjugates Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody-radionuclide Conjugates Revenue in 2024
3.5 Global Key Players of Antibody-radionuclide Conjugates Head office and Area Served
3.6 Global Key Players of Antibody-radionuclide Conjugates, Product and Application
3.7 Global Key Players of Antibody-radionuclide Conjugates, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody-radionuclide Conjugates Breakdown Data by Type
4.1 Global Antibody-radionuclide Conjugates Historic Market Size by Type (2020-2025)
4.2 Global Antibody-radionuclide Conjugates Forecasted Market Size by Type (2026-2031)
5 Antibody-radionuclide Conjugates Breakdown Data by Application
5.1 Global Antibody-radionuclide Conjugates Historic Market Size by Application (2020-2025)
5.2 Global Antibody-radionuclide Conjugates Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antibody-radionuclide Conjugates Market Size (2020-2031)
6.2 North America Antibody-radionuclide Conjugates Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antibody-radionuclide Conjugates Market Size by Country (2020-2025)
6.4 North America Antibody-radionuclide Conjugates Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody-radionuclide Conjugates Market Size (2020-2031)
7.2 Europe Antibody-radionuclide Conjugates Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antibody-radionuclide Conjugates Market Size by Country (2020-2025)
7.4 Europe Antibody-radionuclide Conjugates Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody-radionuclide Conjugates Market Size (2020-2031)
8.2 Asia-Pacific Antibody-radionuclide Conjugates Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antibody-radionuclide Conjugates Market Size by Region (2020-2025)
8.4 Asia-Pacific Antibody-radionuclide Conjugates Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody-radionuclide Conjugates Market Size (2020-2031)
9.2 Latin America Antibody-radionuclide Conjugates Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antibody-radionuclide Conjugates Market Size by Country (2020-2025)
9.4 Latin America Antibody-radionuclide Conjugates Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody-radionuclide Conjugates Market Size (2020-2031)
10.2 Middle East & Africa Antibody-radionuclide Conjugates Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antibody-radionuclide Conjugates Market Size by Country (2020-2025)
10.4 Middle East & Africa Antibody-radionuclide Conjugates Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Antibody-radionuclide Conjugates Introduction
11.1.4 Bayer Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.1.5 Bayer Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Antibody-radionuclide Conjugates Introduction
11.2.4 Novartis Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Lantheus
11.3.1 Lantheus Company Details
11.3.2 Lantheus Business Overview
11.3.3 Lantheus Antibody-radionuclide Conjugates Introduction
11.3.4 Lantheus Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.3.5 Lantheus Recent Development
11.4 Aurobindo Pharma
11.4.1 Aurobindo Pharma Company Details
11.4.2 Aurobindo Pharma Business Overview
11.4.3 Aurobindo Pharma Antibody-radionuclide Conjugates Introduction
11.4.4 Aurobindo Pharma Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.4.5 Aurobindo Pharma Recent Development
11.5 Mundipharma
11.5.1 Mundipharma Company Details
11.5.2 Mundipharma Business Overview
11.5.3 Mundipharma Antibody-radionuclide Conjugates Introduction
11.5.4 Mundipharma Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.5.5 Mundipharma Recent Development
11.6 China Isotope & Radiation
11.6.1 China Isotope & Radiation Company Details
11.6.2 China Isotope & Radiation Business Overview
11.6.3 China Isotope & Radiation Antibody-radionuclide Conjugates Introduction
11.6.4 China Isotope & Radiation Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.6.5 China Isotope & Radiation Recent Development
11.7 Curium Pharmaceuticals
11.7.1 Curium Pharmaceuticals Company Details
11.7.2 Curium Pharmaceuticals Business Overview
11.7.3 Curium Pharmaceuticals Antibody-radionuclide Conjugates Introduction
11.7.4 Curium Pharmaceuticals Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.7.5 Curium Pharmaceuticals Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Details
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Antibody-radionuclide Conjugates Introduction
11.8.4 Gilead Sciences Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.8.5 Gilead Sciences Recent Development
11.9 Clarity Pharmaceuticals
11.9.1 Clarity Pharmaceuticals Company Details
11.9.2 Clarity Pharmaceuticals Business Overview
11.9.3 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Introduction
11.9.4 Clarity Pharmaceuticals Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.9.5 Clarity Pharmaceuticals Recent Development
11.10 Curasight
11.10.1 Curasight Company Details
11.10.2 Curasight Business Overview
11.10.3 Curasight Antibody-radionuclide Conjugates Introduction
11.10.4 Curasight Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.10.5 Curasight Recent Development
11.11 Nordic Nanovector
11.11.1 Nordic Nanovector Company Details
11.11.2 Nordic Nanovector Business Overview
11.11.3 Nordic Nanovector Antibody-radionuclide Conjugates Introduction
11.11.4 Nordic Nanovector Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.11.5 Nordic Nanovector Recent Development
11.12 Philogen
11.12.1 Philogen Company Details
11.12.2 Philogen Business Overview
11.12.3 Philogen Antibody-radionuclide Conjugates Introduction
11.12.4 Philogen Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.12.5 Philogen Recent Development
11.13 RadioMedix
11.13.1 RadioMedix Company Details
11.13.2 RadioMedix Business Overview
11.13.3 RadioMedix Antibody-radionuclide Conjugates Introduction
11.13.4 RadioMedix Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.13.5 RadioMedix Recent Development
11.14 Telix Pharmaceuticals
11.14.1 Telix Pharmaceuticals Company Details
11.14.2 Telix Pharmaceuticals Business Overview
11.14.3 Telix Pharmaceuticals Antibody-radionuclide Conjugates Introduction
11.14.4 Telix Pharmaceuticals Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.14.5 Telix Pharmaceuticals Recent Development
11.15 Orano Med
11.15.1 Orano Med Company Details
11.15.2 Orano Med Business Overview
11.15.3 Orano Med Antibody-radionuclide Conjugates Introduction
11.15.4 Orano Med Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.15.5 Orano Med Recent Development
11.16 Actinium Pharmaceuticals
11.16.1 Actinium Pharmaceuticals Company Details
11.16.2 Actinium Pharmaceuticals Business Overview
11.16.3 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Introduction
11.16.4 Actinium Pharmaceuticals Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.16.5 Actinium Pharmaceuticals Recent Development
11.17 Y-mAbs Therapeutics
11.17.1 Y-mAbs Therapeutics Company Details
11.17.2 Y-mAbs Therapeutics Business Overview
11.17.3 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Introduction
11.17.4 Y-mAbs Therapeutics Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.17.5 Y-mAbs Therapeutics Recent Development
11.18 Fusion Pharmaceuticals
11.18.1 Fusion Pharmaceuticals Company Details
11.18.2 Fusion Pharmaceuticals Business Overview
11.18.3 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Introduction
11.18.4 Fusion Pharmaceuticals Revenue in Antibody-radionuclide Conjugates Business (2020-2025)
11.18.5 Fusion Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
List of Tables
 Table 1. Global Antibody-radionuclide Conjugates Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Beta-emitting
 Table 3. Key Players of Targeted Alpha Therapy
 Table 4. Global Antibody-radionuclide Conjugates Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Antibody-radionuclide Conjugates Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Antibody-radionuclide Conjugates Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Antibody-radionuclide Conjugates Market Share by Region (2020-2025)
 Table 8. Global Antibody-radionuclide Conjugates Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Antibody-radionuclide Conjugates Market Share by Region (2026-2031)
 Table 10. Antibody-radionuclide Conjugates Market Trends
 Table 11. Antibody-radionuclide Conjugates Market Drivers
 Table 12. Antibody-radionuclide Conjugates Market Challenges
 Table 13. Antibody-radionuclide Conjugates Market Restraints
 Table 14. Global Antibody-radionuclide Conjugates Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Antibody-radionuclide Conjugates Market Share by Players (2020-2025)
 Table 16. Global Top Antibody-radionuclide Conjugates Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-radionuclide Conjugates as of 2024)
 Table 17. Ranking of Global Top Antibody-radionuclide Conjugates Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Antibody-radionuclide Conjugates Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Antibody-radionuclide Conjugates, Headquarters and Area Served
 Table 20. Global Key Players of Antibody-radionuclide Conjugates, Product and Application
 Table 21. Global Key Players of Antibody-radionuclide Conjugates, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Antibody-radionuclide Conjugates Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Antibody-radionuclide Conjugates Revenue Market Share by Type (2020-2025)
 Table 25. Global Antibody-radionuclide Conjugates Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Antibody-radionuclide Conjugates Revenue Market Share by Type (2026-2031)
 Table 27. Global Antibody-radionuclide Conjugates Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Antibody-radionuclide Conjugates Revenue Market Share by Application (2020-2025)
 Table 29. Global Antibody-radionuclide Conjugates Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Antibody-radionuclide Conjugates Revenue Market Share by Application (2026-2031)
 Table 31. North America Antibody-radionuclide Conjugates Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Antibody-radionuclide Conjugates Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Antibody-radionuclide Conjugates Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Antibody-radionuclide Conjugates Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Antibody-radionuclide Conjugates Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Antibody-radionuclide Conjugates Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Antibody-radionuclide Conjugates Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Antibody-radionuclide Conjugates Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Antibody-radionuclide Conjugates Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Antibody-radionuclide Conjugates Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Antibody-radionuclide Conjugates Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Antibody-radionuclide Conjugates Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Antibody-radionuclide Conjugates Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Antibody-radionuclide Conjugates Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Antibody-radionuclide Conjugates Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Bayer Company Details
 Table 47. Bayer Business Overview
 Table 48. Bayer Antibody-radionuclide Conjugates Product
 Table 49. Bayer Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 50. Bayer Recent Development
 Table 51. Novartis Company Details
 Table 52. Novartis Business Overview
 Table 53. Novartis Antibody-radionuclide Conjugates Product
 Table 54. Novartis Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 55. Novartis Recent Development
 Table 56. Lantheus Company Details
 Table 57. Lantheus Business Overview
 Table 58. Lantheus Antibody-radionuclide Conjugates Product
 Table 59. Lantheus Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 60. Lantheus Recent Development
 Table 61. Aurobindo Pharma Company Details
 Table 62. Aurobindo Pharma Business Overview
 Table 63. Aurobindo Pharma Antibody-radionuclide Conjugates Product
 Table 64. Aurobindo Pharma Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 65. Aurobindo Pharma Recent Development
 Table 66. Mundipharma Company Details
 Table 67. Mundipharma Business Overview
 Table 68. Mundipharma Antibody-radionuclide Conjugates Product
 Table 69. Mundipharma Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 70. Mundipharma Recent Development
 Table 71. China Isotope & Radiation Company Details
 Table 72. China Isotope & Radiation Business Overview
 Table 73. China Isotope & Radiation Antibody-radionuclide Conjugates Product
 Table 74. China Isotope & Radiation Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 75. China Isotope & Radiation Recent Development
 Table 76. Curium Pharmaceuticals Company Details
 Table 77. Curium Pharmaceuticals Business Overview
 Table 78. Curium Pharmaceuticals Antibody-radionuclide Conjugates Product
 Table 79. Curium Pharmaceuticals Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 80. Curium Pharmaceuticals Recent Development
 Table 81. Gilead Sciences Company Details
 Table 82. Gilead Sciences Business Overview
 Table 83. Gilead Sciences Antibody-radionuclide Conjugates Product
 Table 84. Gilead Sciences Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 85. Gilead Sciences Recent Development
 Table 86. Clarity Pharmaceuticals Company Details
 Table 87. Clarity Pharmaceuticals Business Overview
 Table 88. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product
 Table 89. Clarity Pharmaceuticals Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 90. Clarity Pharmaceuticals Recent Development
 Table 91. Curasight Company Details
 Table 92. Curasight Business Overview
 Table 93. Curasight Antibody-radionuclide Conjugates Product
 Table 94. Curasight Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 95. Curasight Recent Development
 Table 96. Nordic Nanovector Company Details
 Table 97. Nordic Nanovector Business Overview
 Table 98. Nordic Nanovector Antibody-radionuclide Conjugates Product
 Table 99. Nordic Nanovector Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 100. Nordic Nanovector Recent Development
 Table 101. Philogen Company Details
 Table 102. Philogen Business Overview
 Table 103. Philogen Antibody-radionuclide Conjugates Product
 Table 104. Philogen Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 105. Philogen Recent Development
 Table 106. RadioMedix Company Details
 Table 107. RadioMedix Business Overview
 Table 108. RadioMedix Antibody-radionuclide Conjugates Product
 Table 109. RadioMedix Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 110. RadioMedix Recent Development
 Table 111. Telix Pharmaceuticals Company Details
 Table 112. Telix Pharmaceuticals Business Overview
 Table 113. Telix Pharmaceuticals Antibody-radionuclide Conjugates Product
 Table 114. Telix Pharmaceuticals Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 115. Telix Pharmaceuticals Recent Development
 Table 116. Orano Med Company Details
 Table 117. Orano Med Business Overview
 Table 118. Orano Med Antibody-radionuclide Conjugates Product
 Table 119. Orano Med Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 120. Orano Med Recent Development
 Table 121. Actinium Pharmaceuticals Company Details
 Table 122. Actinium Pharmaceuticals Business Overview
 Table 123. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product
 Table 124. Actinium Pharmaceuticals Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 125. Actinium Pharmaceuticals Recent Development
 Table 126. Y-mAbs Therapeutics Company Details
 Table 127. Y-mAbs Therapeutics Business Overview
 Table 128. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product
 Table 129. Y-mAbs Therapeutics Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 130. Y-mAbs Therapeutics Recent Development
 Table 131. Fusion Pharmaceuticals Company Details
 Table 132. Fusion Pharmaceuticals Business Overview
 Table 133. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product
 Table 134. Fusion Pharmaceuticals Revenue in Antibody-radionuclide Conjugates Business (2020-2025) & (US$ Million)
 Table 135. Fusion Pharmaceuticals Recent Development
 Table 136. Research Programs/Design for This Report
 Table 137. Key Data Information from Secondary Sources
 Table 138. Key Data Information from Primary Sources
 Table 139. Authors List of This Report


List of Figures
 Figure 1. Antibody-radionuclide Conjugates Picture
 Figure 2. Global Antibody-radionuclide Conjugates Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Antibody-radionuclide Conjugates Market Share by Type: 2024 VS 2031
 Figure 4. Beta-emitting Features
 Figure 5. Targeted Alpha Therapy Features
 Figure 6. Global Antibody-radionuclide Conjugates Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Antibody-radionuclide Conjugates Market Share by Application: 2024 VS 2031
 Figure 8. Solid Tumor Case Studies
 Figure 9. Non Hodgkin Lymphoma Case Studies
 Figure 10. Antibody-radionuclide Conjugates Report Years Considered
 Figure 11. Global Antibody-radionuclide Conjugates Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 12. Global Antibody-radionuclide Conjugates Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Antibody-radionuclide Conjugates Market Share by Region: 2024 VS 2031
 Figure 14. Global Antibody-radionuclide Conjugates Market Share by Players in 2024
 Figure 15. Global Top Antibody-radionuclide Conjugates Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-radionuclide Conjugates as of 2024)
 Figure 16. The Top 10 and 5 Players Market Share by Antibody-radionuclide Conjugates Revenue in 2024
 Figure 17. North America Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 18. North America Antibody-radionuclide Conjugates Market Share by Country (2020-2031)
 Figure 19. United States Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. Canada Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Europe Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Antibody-radionuclide Conjugates Market Share by Country (2020-2031)
 Figure 23. Germany Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. France Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. U.K. Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Italy Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Russia Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Nordic Countries Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Asia-Pacific Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Antibody-radionuclide Conjugates Market Share by Region (2020-2031)
 Figure 31. China Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Japan Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. South Korea Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Southeast Asia Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. India Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Australia Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Latin America Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Antibody-radionuclide Conjugates Market Share by Country (2020-2031)
 Figure 39. Mexico Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Brazil Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Middle East & Africa Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Antibody-radionuclide Conjugates Market Share by Country (2020-2031)
 Figure 43. Turkey Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Saudi Arabia Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. UAE Antibody-radionuclide Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Bayer Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 47. Novartis Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 48. Lantheus Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 49. Aurobindo Pharma Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 50. Mundipharma Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 51. China Isotope & Radiation Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 52. Curium Pharmaceuticals Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 53. Gilead Sciences Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 54. Clarity Pharmaceuticals Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 55. Curasight Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 56. Nordic Nanovector Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 57. Philogen Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 58. RadioMedix Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 59. Telix Pharmaceuticals Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 60. Orano Med Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 61. Actinium Pharmaceuticals Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 62. Y-mAbs Therapeutics Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 63. Fusion Pharmaceuticals Revenue Growth Rate in Antibody-radionuclide Conjugates Business (2020-2025)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Targeted PSMA Radionuclide Drug Conjugates Market Research Report 2024
Global Targeted Radionuclide Therapy Market Research Report 2024
Global Conjugated Monoclonal Antibodies Market Research Report 2024
Global Therapeutic Radioligands Market Research Report 2024
Global RDC Radionuclide Drug Conjugate Services Market Research Report 2024
Global Targeted SSTR Radionuclide Drug Conjugates Market Research Report 2024
Global Therapeutic Monoclonal Antibodies Market Research Report 2024
Global Monoclonal Antibody Drugs for Cancer Market Research Report 2024
Global Targeted Radiopharmaceuticals Market Research Report 2024
Global Therapeutic Monoclonal Antibodies Drug Market Research Report 2024
Antibody drug Conjugate for Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Systemic Radiotherapy Market Research Report 2024
Global Antibody drug Conjugates Market Insights Forecast to 2030
Global Antibody Drug Conjugate CDMO Market Research Report 2024
Global Cancer Antibody Drug Conjugates Market Research Report 2024
Global Antibody drug Conjugates for Tumors Market Research Report 2024
Global Nuclear Antigen Monoclonal Antibody Market Research Report 2024
Global Targeted Radiotherapy Drug Market Research Report 2024
Global Radioimmunotherapy Market Research Report 2025
Global Antibody PMO Conjugates Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions